Completed

Genetic Linkage Analysis for Chiari I Malformation

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This study aims to observe family genetics to identify gene locations related to Chiari I malformation and the underdevelopment of certain skull bones.

What is being collected

Data Collection

Collected from today forward - Prospective
Who is being recruted

Congenital Abnormalities+17

+ Carbohydrate Metabolism, Inborn Errors

+ Central Nervous System Diseases

Over 1 Years
+6 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Family-Based

Studying health outcomes within families in order to identify genetic or familial contributions to disease.
Observational
Study Start: June 2001
See protocol details

Summary

Principal SponsorNational Institute of Neurological Disorders and Stroke (NINDS)
Last updated: September 8, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: June 4, 2001

Actual date on which the first participant was enrolled.

Objectives: The goal of this study is to establish family pedigrees and undertake genetic linkage analysis that will identify gene loci associated with the Chiari I malformation and underdevelopment of the bone forming the posterior cranial fossa. Study Population: Patients and family members of patients with the Chiari I malformation. Because the research institutions are located in the United States and Russia, subjects will be recruited predominantly from these countries. Design: Human subjects will undergo 1) neurologic examinations, 2) head and cervical MRI scans to evaluate for the Chiari I malformation, syringomyelia, and maldevelopment of the posterior fossa, and 3) isolation and analysis of genomic DNA from whole blood for linkage analysis. Outcome Measures: Pedigrees will be established based on the MRI findings. The Chiari I phenotype will be defined as the caudal portion of the cerebellar tonsils lying greater than or equal to 2 mm below the foramen magnum and underdevelopment of the bone of the posterior fossa will be defined as 1) obliteration of the CSF pathways in the inferior portion of the posterior fossa, 2) posterior fossa volume to supratentorial volume ratio of less than or equal to 15%, or 3) abnormal shortening of the bones of the skull base. Genetic analysis of the genomic DNA will be performed with DNA polymorphic markers to identify chromosomal loci linked to the small posterior fossa phenotype. A lod score of 3.0 (equivalent to 1000:1 odds in favor of linkage) will be taken as proof that the Chiari I gene maps to the same genetic region of the human genome as a given DNA marker.

NCT00004738
Principal SponsorNational Institute of Neurological Disorders and Stroke (NINDS)
Last updated: September 8, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

152 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Family-Based

These studies involve members of the same family to explore how genetics and shared environments may contribute to a disease. They help researchers pinpoint inherited risk factors.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 1 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Congenital AbnormalitiesCarbohydrate Metabolism, Inborn ErrorsCentral Nervous System DiseasesConnective Tissue DiseasesMetabolic DiseasesMetabolism, Inborn ErrorsMucopolysaccharidosesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesNervous System MalformationsNervous System DiseasesNeural Tube DefectsNutritional and Metabolic DiseasesSpinal Cord DiseasesLysosomal Storage DiseasesSkin and Connective Tissue DiseasesMucinosesGenetic Diseases, InbornArnold-Chiari MalformationMucopolysaccharidosis IVSyringomyelia

Criteria

2 inclusion criteria required to participate
If an adult, able to give informed consent; if a minor, has an adult who is legally responsible for the subject and who is able to give consent

Patient with a confirmed diagnosis of Chiari I malformation who has a family member with syringomyelia or Chiari I malformation, or Family member of a patient with a confirmed diagnosis of Chiari I malformation, AND There are at least two family members diagnosed with Chiari I malformation

4 exclusion criteria prevent from participating
Cannot undergo MRI scanning without sedation

Has a contraindication to MRI scanning

Is less than one year of age

Is unable to comprehend the risks of the testing

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 2 locations

National Institutes of Health Clinical Center

Bethesda, United StatesOpen National Institutes of Health Clinical Center in Google Maps

Kazan State Medical University

Kazan', Russia
Completed2 Study Centers